GLYC - GlycoMimetics, Inc.
| Previous Close | 14.25 |
| Open | 14.22 |
| Bid | 13.92 x 1300 |
| Ask | 16.60 x 800 |
| Day's Range | 14.04 - 14.69 |
| 52 Week Range | 10.41 - 26.05 |
| Volume | 302,403 |
| Avg. Volume | 296,639 |
| Market Cap | 609.261M |
| Beta (3Y Monthly) | 3.60 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.11 |
| Earnings Date | Aug 3, 2017 - Aug 7, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.00 |
- Zacks•11 days ago
Neurocrine Inks Deal with Private Biotech to Make CNS Drugs
Neurocrine (NBIX) collaborates with Jnana Therapeutics to develop novel small-molecule therapies for multiple targets of central nervous system (CNS) disorders.
- GlobeNewswire•2 months ago
Research Report Identifies FS Investment, Rush Enterprises, GlycoMimetics, Federal Signal, ATN International, and Novavax with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Aug. 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of FS ...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of GLYC earnings conference call or presentation 10-Aug-18 12:30pm GMT
Q2 2018 GlycoMimetics Inc Earnings Call
- Business Wire•2 months ago
GlycoMimetics Receives Japanese Patent For Uproleselan (GMI-1271)
GlycoMimetics, Inc. (GLYC), a biopharmaceutical company focused on discovering and developing novel small-molecule drug candidates to treat rare diseases, announced today that the Japan Patent Office (JPO) has issued Patent No. 6366150, for uproleselan (GMI-1271). The newly issued patent covers uproleselan’s composition of matter as well as pharmaceutical formulations, and expires in December 2032. “The JPO’s issuance of a patent for uproleselan extends major market intellectual property coverage for this E-selectin antagonist drug candidate,” stated Rachel King, GlycoMimetics’ Chief Executive Officer.
Motley Fool•2 months agoGlycoMimetics (GLYC) Q2 2018 Earnings Conference Call Transcript
GLYC earnings call for the period ending June 30, 2018.
- InvestorPlace•2 months ago
GlycoMimetics Stock Has Substantial Upside
GlycoMimetics (NASDAQ:GLYC) issued a second quarter earnings report that investors will like. Its cash position was at high enough levels to cover future operational needs. GlycoMimetics ended the second quarter (Jun. 30, 2018) with $229.4 million in cash.
- ACCESSWIRE•2 months ago
GlycoMimetics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 10, 2018 / GlycoMimetics, Inc. (NASDAQ: GLYC ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 10, 2018 at 8:30 AM Eastern Time. ...
- Associated Press•2 months ago
GlycoMimetics: 2Q Earnings Snapshot
On a per-share basis, the Rockville, Maryland-based company said it had a loss of 26 cents. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
- Business Wire•2 months ago
GlycoMimetics Reports Second Quarter 2018 Results and Highlights Recent Company Achievements
ROCKVILLE, Md.-- -- Announced a Cooperative Research and Development Agreement to collaborate with the National Cancer Institute and the Alliance for Clinical Trials in Oncology to fund a planned pivotal Phase 3 trial to evaluate uproleselan in older, newly diagnosed acute myeloid leukemia patients eligible for intensive chemotherapy Continued to select new clinical sites and ready previously-selected ...
- Business Wire•3 months ago
GlycoMimetics to Report Second Quarter 2018 Financial Results on August 9, 2018
GlycoMimetics, Inc. (GLYC) announced today that it will report its second quarter 2018 financial results on Thursday August 9, 2018, and will host a conference call and webcast on Friday, August 10, 2018, at 8:30 a.m. ET. To access the live audio webcast, or the subsequent archived recording, visit the “Investors - Events & Presentations” section of the GlycoMimetics website at www.glycomimetics.com. The webcast will be recorded and available for replay on the GlycoMimetics website for 30 days following the call.
- GlobeNewswire•3 months ago
Factors of Influence in 2018, Key Indicators and Opportunity within Minerals Technologies, USG, Continental Resources, Take-Two Interactive Software, Trimble, and GlycoMimetics — New Research Emphasizes Economic Growth
NEW YORK, July 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Minerals ...
- ACCESSWIRE•3 months ago
Free Daily Technical Summary Reports on Iovance Biotherapeutics and Three Other Biotech Stocks
LONDON, UK / ACCESSWIRE / July 18, 2018 / If you want a free Stock Review on IOVA sign up now at www.wallstequities.com/registration. Gains were broad based as six out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Biotechnology stocks: GlycoMimetics Inc. (NASDAQ: GLYC), Iovance Biotherapeutics Inc. (NASDAQ: IOVA), Jaguar Health Inc. (NASDAQ: JAGX), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ).
- ACCESSWIRE•4 months ago
Free Technical Reports on Gilead Sciences and Three Additional Biotech Equities
On Wednesday, June 13, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Eight out of nine sectors ended Wednesday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Geron Corp. (NASDAQ: GERN), Gilead Sciences Inc. (NASDAQ: GILD), Global Blood Therapeutics Inc. (NASDAQ: GBT), and GlycoMimetics Inc. (NASDAQ: GLYC).
- Business Wire•5 months ago
GlycoMimetics to Present at Jefferies 2018 Global Healthcare Conference
GlycoMimetics, Inc. today announced that Chief Executive Officer Rachel King will provide a company overview at the Jefferies Annual Health Care Conference in New York, on Thursday, June 7, 2018, at 11:30 a.m.
- Business Wire•5 months ago
GlycoMimetics Announces NCI-Sponsored Pivotal Trial of GMI-1271 in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy
GlycoMimetics, Inc. (GLYC), a biopharmaceutical company focused on discovering and developing novel small-molecule drug candidates to treat rare diseases, announced today it had signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). Under the terms of the CRADA, GlycoMimetics will collaborate with both the NCI and the Alliance for Clinical Trials in Oncology to conduct a randomized, controlled clinical trial testing the addition of GMI-1271 to a standard cytarabine/daunorubicin regimen (7&3) in older adults with previously untreated acute myelogenous leukemia (AML) who are suitable for intensive chemotherapy.
- Thomson Reuters StreetEvents•6 months ago
Edited Transcript of GLYC earnings conference call or presentation 3-May-18 12:30pm GMT
Q1 2018 GlycoMimetics Inc Earnings Call
- Associated Press•6 months ago
GlycoMimetics: 1Q Earnings Snapshot
The Rockville, Maryland-based company said it had a loss of 33 cents per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
- Business Wire•6 months ago
GlycoMimetics Reports First Quarter 2018 Results
GlycoMimetics, Inc. today reported its financial results for the first quarter ended March 31, 2018 and highlighted recent company achievements. Quarter-end cash as a result of a follow-on financing in March was $242.6 million.
- Business Wire•6 months ago
GlycoMimetics to Report First Quarter 2018 Financial Results on May 3, 2018
GlycoMimetics, Inc. (GLYC) announced today that it will host a conference call and webcast to report its first quarter 2018 financial results on Thursday, May 3, 2018, at 8:30 a.m. ET. To access the live audio webcast, or the subsequent archived recording, visit the “Investors - Events & Presentations” section of the GlycoMimetics website at www.glycomimetics.com. The webcast will be recorded and available for replay on the GlycoMimetics website for 30 days following the call.
- Business Wire•7 months ago
GlycoMimetics Announces Pricing of Public Offering of Common Stock
GlycoMimetics, Inc. , a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced the pricing of its underwritten public offering of 7,000,000 shares of its common stock at a price to the public of $17.00 per share.
- Business Wire•7 months ago
GlycoMimetics Announces Proposed Public Offering of Common Stock
GlycoMimetics, Inc. , a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs, today announced that it intends to offer and sell, subject to market conditions, 4,500,000 shares of its common stock in an underwritten public offering.
- Business Wire•7 months ago
GlycoMimetics to Present New Preclinical Data for GMI-1271 and GMI-1359 at AACR Annual Meeting 2018
GlycoMimetics, Inc. announced today that preclinical research suggesting the potential of two of its drug candidates, GMI-1271 and GMI-1359, as treatments for acute myeloid leukemia , metastasis in osteosarcoma and other cancers will be shared via poster presentations at the American Association for Cancer Research Annual Meeting 2018 in Chicago.
- Business Wire•7 months ago
GlycoMimetics to Present at Four Investor Conferences This Month
GlycoMimetics, Inc. announced today that it will present at four investor conferences during the month of March, including:
